VasSol said last week that results from a trial of its Nova non-invasive optimal vessel analysis showed that the device was able to identify critical trial patients at higher risk of recurrent stroke. The results from the study were published in the JAMA Neurology journal.
Results from the 6-year, multi-center Veritas trial indicated that patients who experience a stroke in the back of their brain, and continue to have reduced blood flow to the area, have a higher risk of having another stroke within 2 years.
“Nova is the only technology that can visualize and quantify the volume, speed and direction of blood flowing through any major vessel of the brain. Identifying those at highest risk for a stroke makes studying the condition easier and leads to better, more precise therapies and more focused implementation of healthcare resources,” chief science officer Dr. Fady Charbel said in a press release.
VasSol said results from the trial are “expected to change the standard of care for posterior stroke victims,” who make up approximately 40% of all stroke victims.
“We believe that Nova should be included in the clinical and imaging assessment of posterior circulation stroke patients. At Northwestern, we’re using it in the current Myriad trial to further broaden its application in stroke-risk diagnosis and treatment planning,” Dr. Shyam Prabhakaran of Northwestern University’s Feinberg School of Medicine said in a prepared statement.
VasSol’s Nova software uses magnetic resonance imaging equipment to assess blood flow in the back of patient’s brains, the company said. The system has been designed to also assess blood-flow information about vessels in other regions of the body, including kidneys, lower extremities and hands.
The Nova won FDA clearance in 2001, and is installed in more than 40 hospitals across the U.S., the company said.
“Nova helps answer fundamental questions that clinicians confront when treating vascular disease, such as what is the severity, how is the condition best treated, and what is the outcome. Physicians can now be confident in prescribing procedures such as balloon angioplasty and stenting to low blood-flow patients who are most at risk for another stroke. Patients with more normal blood-flow levels may be able to avoid those procedures and the associated risks,” CEO Chuck Doherty said in prepared remarks.